Myriad Genetics, Inc. : A well-established uptrend
November 26, 2012 at 12:52 pm EST
By
Share
BUY
Live
Entry price
Target
Stop-loss
Potential
$30.38
$0
$28.5
-100%
Myriad Genetics continues its bullish trend in order to test new highest level.
From a fundamental viewpoint, the company is strong. The Thomson Reuters consensus revised regularly upward EPS estimates of the company for the current year. The great business predictability emphasize the quality of this investment in the mid-term.
Technically, the security shows a bullish configuration on all time scales. Prices are supported by increasing moving averages.
According to both technical and fundamental elements, it seems opportune to take a long position at the current price. The bullish trend should allow the security to reach the USD 32.6 resistance. If the stock crosses it, a new target price will be set. A stop loss will be placed under the 20-day moving average to avoid a downtrend.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.
MYRIAD GENETICS, INC. 
